Home/Pipeline/Target 2

Target 2

Not Disclosed

DiscoveryActive

Key Facts

Indication

Not Disclosed

Phase

Discovery

Status

Active

Company

Remedy Plan Therapeutics

About Remedy Plan Therapeutics

Remedy Plan Therapeutics is pioneering a novel approach to NAMPT inhibition, a core metabolic enzyme implicated in over 20 diseases including cancer, autoimmune disorders, and obesity. Its proprietary drug screening platform has yielded RPT1G, a first-in-class clinical candidate with an unprecedented allosteric mechanism aimed at delivering efficacy without the severe toxicity of prior NAMPT inhibitors. The company is advancing RPT1G in oncology while leveraging its platform to discover new drugs for autoimmune and metabolic indications. With its lead program now in Phase 1, Remedy Plan is positioned to validate a new therapeutic paradigm for a high-value but historically intractable target.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Metabolic Disorders

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active